The clinical-stage company Algernon Pharmaceuticals (CSE:AGN; Frankfurt:AGW0; OTCQB: AGNPF) has received approval to run a Phase 1 clinical study of an IV formulation of AP-188.
The study will explore the drug candidate’s potential, a formulation of the classic psychedelic N,N-dimethyl tryptamine or DMT, to treat stroke patients in the Netherlands.
The Stichting Beoordeling Ethiek Biomedisch Onderzoek (“BEBO”), an independent medical research ethics committee, will manage the study.
Algernon decided to investigate the potential of DMT in human studies for ischemic stroke after reviewing data from independent studies demonstrating that DMT can mitigate tissue damage while promoting neurogenesis and neuroplasticity.
To learn more about Algernon’s plans to explore the potential of DMT as a therapy for ischemic stroke, we spoke with Christopher J. Moreau, the company’s CEO.
What led to your interest in DMT as a potent…